Sahar A. Saddoughi, Ph.D.
Affiliations: | 2013 | Medical University of South Carolina, Charleston, SC, United States |
Area:
General Biology, Molecular Biology, OncologyGoogle:
"Sahar Saddoughi"Mean distance: (not calculated yet)
Parents
Sign in to add mentor| Besim Ogretmen | grad student | 2013 | MUSC | |
| (FTY720 Mimics Ceramide to Target I2PP2A/SET Oncoprotein for PP2A Activation leading to Lung Tumor Suppression.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Neviani P, Harb JG, Oaks JJ, et al. (2013) PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. The Journal of Clinical Investigation. 123: 4144-57 |
| Oaks JJ, Santhanam R, Walker CJ, et al. (2013) Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies. Blood. 122: 1923-34 |
| Saddoughi SA, Ogretmen B. (2013) Diverse functions of ceramide in cancer cell death and proliferation. Advances in Cancer Research. 117: 37-58 |
| Saddoughi SA, Gencer S, Peterson YK, et al. (2013) Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis. Embo Molecular Medicine. 5: 105-21 |
| Meyers-Needham M, Lewis JA, Gencer S, et al. (2012) Off-target function of the Sonic hedgehog inhibitor cyclopamine in mediating apoptosis via nitric oxide-dependent neutral sphingomyelinase 2/ceramide induction. Molecular Cancer Therapeutics. 11: 1092-102 |
| Simon GR, Saddoughi S, Mukhopadhyay A, et al. (2011) Targeting I2PP2A by FTY720: A novel, mechanism-based treatment strategy for patients with advanced and previously treated non-small cell lung cancer (NSCLC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 7574 |
| Shirai K, Saddoughi S, O'Brien PE, et al. (2011) Serum C18-ceramide as a biomarker for response: Phase II trial of gemcitabine plus doxorubicin in patients with HNSCC. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 5590 |
| Senkal CE, Ponnusamy S, Manevich Y, et al. (2011) Alteration of ceramide synthase 6/C16-ceramide induces activating transcription factor 6-mediated endoplasmic reticulum (ER) stress and apoptosis via perturbation of cellular Ca2+ and ER/Golgi membrane network. The Journal of Biological Chemistry. 286: 42446-58 |
| Saddoughi SA, Garrett-Mayer E, Chaudhary U, et al. (2011) Results of a phase II trial of gemcitabine plus doxorubicin in patients with recurrent head and neck cancers: serum Câ‚₈-ceramide as a novel biomarker for monitoring response. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 6097-105 |
| Salas A, Ponnusamy S, Senkal CE, et al. (2011) Sphingosine kinase-1 and sphingosine 1-phosphate receptor 2 mediate Bcr-Abl1 stability and drug resistance by modulation of protein phosphatase 2A. Blood. 117: 5941-52 |